Vivesto AB is a specialty pharmaceutical company that is dedicated to developing innovative therapeutic options for patients facing difficult-to-treat cancers. With a focus on human and veterinary oncology, they are at the forefront of the next generation of drug development. Their emerging pipeline of clinical-stage assets is specifically tailored to address late-stage cancers.

Apealea® (paclitaxel micellar) is one such development, and it is being made accessible to ovarian cancer patients through a strategic partnership with Elevar Therapeutics, Inc. Additionally, Vivesto is actively working on Cantrixil, intended for late-stage ovarian cancer, as well as docetaxel micellar, targeting advanced prostate cancer. What sets Vivesto apart is their proprietary drug delivery technology, which enhances solubility, efficacy, and safety.

By leveraging this technology, they aim to improve patient outcomes and provide much-needed relief to individuals facing challenging cancer diagnoses. Vivesto's dedication to their mission is evident in their commitment to sustainability and corporate responsibility. They strive to make a meaningful impact on the lives of patients, partnering with industry leaders and constantly advancing their therapeutic offerings.

With a deep passion for innovation and patient well-being, Vivesto is poised to revolutionize cancer treatment